***N*⁶-methyladenosine in poly(A) tails stabilize VSG transcripts**

Idalio J. Viegas¹, Juan Pereira de Macedo¹, Mariana De Niz¹, João A. Rodrigues²,
Francisco Aresta-Branco^{3,4}, Samie R. Jaffrey⁵, Luisa M. Figueiredo^{1*}

1. Instituto de Medicina Molecular – João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa 1649-028, Portugal
2. Clarify Analytical, Rua dos Mercadores 128A, 7000-872 Évora, Portugal
3. Division of Immune Diversity, German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
4. Division of Structural Biology of Infection and Immunity, German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
5. Department of Pharmacology, Weill Medical College, Cornell University, New York, NY, USA

*corresponding address: lmf@medicina.ulisboa.pt

Keywords

*N*⁶-methyladenosine, m⁶A, RNA stability, RNA modification, trypanosomes, VSG, antigenic variation, poly(A) tail

Summary

RNA modifications are important regulators of gene expression. In *Trypanosoma brucei*, transcription is polycistronic and thus most regulation happens post-transcriptionally. *N*⁶-methyladenosine (m⁶A) has been detected in this parasite, but its function remains unknown. Here we show that ~50% of the m⁶A is located in the poly(A) tail of the monoallelically expressed Variant Surface Glycoprotein (VSG) transcript. m⁶A residues are removed from the VSG poly(A) tail prior to deadenylation and mRNA degradation. Using genetic tools, we identified a 16-mer motif in the 3'UTR of VSG that acts as a cis-acting motif required for inclusion of m⁶A in the poly(A) tail. Removal of this motif from the VSG 3' UTR results in poly(A) tails lacking m⁶A, rapid deadenylation and mRNA degradation. To our knowledge this is the first identification of an RNA modification in the poly(A) tail of any eukaryote, uncovering a novel post-transcriptional mechanism of gene regulation.

Introduction

Trypanosoma brucei (*T. brucei*) is a protozoan unicellular parasite that causes lethal diseases in sub-Saharan Africa: sleeping sickness in humans and nagana in cattle¹. In humans, the infection can last several months or years mostly because *T. brucei* escapes the immune system by periodically changing its variant surface glycoprotein (VSG)². The *T. brucei* genome contains around 2000 antigenically distinct VSG genes, but only one VSG gene is actively transcribed at a given time. Transcriptionally silent VSG genes are switched on by homologous recombination into the BES or by transcriptional activation of a new BES², resulting in parasites covered by ~10 million identical copies of the VSG protein³.

VSG is essential for the survival of bloodstream form parasites. VSG is not only one of the most abundant proteins in *T. brucei*, but it is also the most abundant mRNA in bloodstream forms (4-11% of total mRNA)^{4,5}. VSG mRNA abundance is a consequence of its unusual transcription by RNA polymerase I and its prolonged stability. The half-life of VSG mRNA has been estimated to range from 90-270 min, contrasting with the 12 min, on average, for other transcripts⁶. The basis for its unusually high stability is not known. It is thought to derive from the VSG 3'UTR, which contains two conserved motifs, a 9-mer and a 16-mer motif, found immediately upstream of the poly(A) tail. Mutational studies have shown that the 16-mer conserved motif is essential for VSG mRNA high abundance and stability⁷, even though its underlying mechanism is unknown.

VSG expression is highly regulated when the bloodstream form parasites undergo differentiation to the procyclic forms that proliferate in the insect vector⁸. The BES becomes transcriptionally silenced and VSG mRNA becomes unstable⁹, which results in rapid loss of VSG mRNA and replacement of the VSG coat protein by other surface proteins (reviewed in¹⁰). The mechanism by which VSG mRNA becomes unstable during differentiation remain unknown. The surface changes are accompanied by additional metabolic and morphological adaptations, which allow procyclic forms to survive in a different environment in the insect host¹⁰.

RNA modifications have been recently identified as important means of regulating gene expression. The most abundant internal modified nucleotide in eukaryotic mRNA is N⁶-methyladenosine (m⁶A)^{11,12}, which is widespread across the human and mouse transcriptomes and is often found near stop codons and the 3' untranslated regions of the mRNA encoded by multiple genes^{13,14}. m⁶A is synthesized by a methyltransferase complex whose catalytic subunit, METTL3, methylates adenosine in a specific consensus motif. Demethylases responsible for removing m⁶A from mRNA have also been identified. m⁶A affects several aspects of RNA biology, for instance contributing to mRNA stability, mRNA translation, or affecting alternative polyadenylation site selection (reviewed in¹⁵).

Here we show that N⁶-methyladenosine is an RNA modification enriched in *T. brucei* mRNA. Importantly, this study revealed that m⁶A is present in mRNA poly(A) tails, and half of m⁶A is located in only one transcript (VSG mRNA). We identified a cis-acting element required for inclusion of m⁶A at the VSG poly(A) tail and, by genetically manipulating this motif, we showed that m⁶A blocks poly(A) deadenylation, hence promoting VSG mRNA stability. We provide the first

evidence that poly(A) tails of mRNA can be methylated in eukaryotes, playing a regulatory role in the control of gene expression.

Results

m⁶A is present in *T. brucei* messenger RNA

To investigate if *T. brucei* RNA harbours modified nucleosides that could play a role in gene regulation, we used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to detect possible modifications of RNA nucleosides. Thirty seven possible modified nucleosides were found in total RNA (Table S1), most of which had been previously detected in *T. brucei* RNA including Am, which is found in the mRNA cap structure, and m³C, m⁵C and Gm in tRNA and rRNA^{16–18}. Mass-spectrometry analysis of mRNA revealed a clear peak that corresponded to m⁶A. Given the importance of this modification for RNA metabolism in other eukaryotes, we focused on this specific modification in *T. brucei*.

First, we tested if m⁶A was mainly present in mRNA, or if it was present in other type of RNA molecules (rRNA, tRNA and other non-coding RNAs). We also compared two different stages of the parasite life cycle, the mammalian bloodstream and the insect procyclic forms. An m⁶A nucleoside standard was used as a control. The chromatograms of the poly(A)-enriched fraction (mRNA) revealed a single peak corresponding to the 282→150 mass transition and an elution time of 10 min (Fig. 1A), confirming it represents m⁶A. The chromatograms of total RNA and poly(A)-depleted samples also contained a peak with an identical mass transition, but the elution time was much earlier (6.5 min), which likely reflects N¹-methyladenosine (m¹A), a modification with the same mass and earlier elution times, and is commonly found in rRNAs and tRNAs^{19,20}. The m⁶A peak in poly(A)-depleted RNA was barely detectable, indicating that most (if not all) m⁶A is present in mRNA and absent from rRNA and tRNAs. Similar results were obtained in RNA fractions obtained from the procyclic form insect stage (Extended Data Fig. S1A).

The m⁶A standard allowed us to quantify the abundance of m⁶A in both stages of the life cycle (Extended Data Fig. S1B). As expected, the levels are very low in total and poly(A)-depleted fractions. In contrast, in both bloodstream and procyclic forms mRNA fractions, m⁶A represents 0.06% of total adenines in mRNA (Fig. 1B). In other words, 6 in 10,000 adenosines contain a methyl group at position 6. This proportion is lower than in mammalian cells (0.1-0.4%,^{11,12}).

Figure 1. m⁶A is present in *T. brucei* mRNA in both insect and mammalian stages of the life cycle.

a. Chromatograms obtained based on an LC-MS/MS analysis of a m⁶A standard and three RNA samples of *T. brucei* mammalian stages (BSF): total RNA, RNA enriched with oligo(dT)-beads (i.e., poly(A)-enriched RNA) and RNA that did not bind poly(T)-beads (i.e., poly(A)-depleted RNA). RNA was hydrolyzed and dephosphorylated and individual nucleosides were resolved by HPLC. m⁶A was readily detected in the poly(A)-enriched RNA. Another peak eluting at ~6.6 min, corresponding to the tRNA and rRNA-enriched nucleotide m¹A, was detected in the poly(A)-depleted and total RNA samples. Identical analysis was performed in RNA from the insect life-cycle stage (PCF) – Fig. S1A. **b.** Levels of m⁶A detected by LC-MS/MS in the RNA samples indicated in panel (A) and quantified using the standard curve in Fig. S1B.

(see also Extended Data Fig. S1)

m⁶A is enriched in the VSG poly(A) tail

During their life cycle, parasites need to adapt to living in different environments. The most recent studies have shown that around 30% of transcripts and around 33-40% of proteins are differentially expressed between these two life cycle stages^{21,22}. It is possible that m⁶A is not equally distributed qualitatively and quantitatively in the transcripts of the two stages of the life cycle. To test this hypothesis, we performed immunoblotting with an antibody that recognizes m⁶A. This antibody specifically recognizes m⁶A with minimal cross-reaction with unmodified adenosine or m¹A (Extended Data Fig. S2). Mouse liver total RNA was used as a control. As expected¹³, the immunoblotting of liver total RNA revealed a smear in the entire lane, indicating that multiple RNA molecules of different sizes harbour m⁶A (Fig. 2A).

Next, we examined m⁶A in total RNA, poly(A)-enriched and poly(A)-depleted RNAs derived from bloodstream and procyclic forms (Fig. 2A). Consistent with the results obtained by LC-MS/MS, the poly(A)-depleted fraction showed a weak m⁶A signal, revealing that m⁶A is absent or below detection levels in rRNAs and tRNAs. In contrast, an m⁶A-positive smear was detected in poly(A)-enriched fraction both in bloodstream and procyclic forms, confirming that m⁶A is present in multiple mRNA molecules in both stages of the life cycle. Strikingly, however, the sample of bloodstream forms revealed an intense band of around 1.8 kb. This band accounts for ~50% of the m⁶A signal intensity in the lane (Fig. 2B), suggesting that m⁶A in bloodstream forms is highly enriched in one type or several similarly sized types of transcripts.

The most abundant transcript in bloodstream forms is the *VSG*, which accounts for ~5% of the total mRNA⁵. To test if the specific band is *VSG*, we repeated the immunoblot assay but site-selectively cleaved the *VSG* transcript with Ribonuclease H (RNase H) and monitored the mobility of the m⁶A band. Poly(A) RNA was incubated with DNA oligonucleotides that annealed at different sites along the length of the *VSG* transcript. RNase H digestion of the RNA:DNA hybrids result in fragments of predicted sizes (Fig. 2C-D). If the *VSG* transcript is the band with the intense m⁶A signal, the band detected by immunoblotting would “shift” to one or two of the fragments of smaller size.

Figure 2. m⁶A is present in the poly(A) tail of VSG mRNA and other transcripts.

a. Immunoblotting with anti-m⁶A antibody. RNA samples (from left to right): total RNA (Total), Poly(A)-enriched (A+) RNA and Poly(A)-depleted (A-) RNA from two life cycle stages (BSF and PCF). The last lane contains total mouse liver RNA (Mouse). 2 μ g of total RNA, 2 μ g of poly(A)-depleted RNA and 100 ng of poly(A)-enriched RNA was loaded per lane. rRNA was detected by staining RNA with methylene blue to confirm equal loading between total and poly(A)-depleted fractions. As expected the rRNA are undetectable in the poly(A)-enriched fraction. **b.** Intensity of the m⁶A signal in immunoblot, measured by Image J, in the whole lane containing the poly(A)-enriched RNA of bloodstream forms. The intensity of the ~1.8 kb band was compared with the signal intensity of the entire lane, and averaged from 5 independent samples. **c.** Diagram displaying the location of the oligonucleotides used in RNase H digestion of VSG mRNA. The digestion products detected in the immunoblot (panel D) after incubation with each oligonucleotide (SL, A, B, C, dT) are also indicated. **d.** Immunoblotting with anti-m⁶A antibody of mammalian bloodstream forms total RNA pre-incubated with indicated oligonucleotides and digested with RNase H. 2 μ g of total RNA were loaded per lane. Staining of rRNA with Methylene Blue confirmed equal loading. SL: spliced leader, dT: poly deoxy-thymidines. Tub: α -Tubulin. (see also Extended Data Fig. S3)

We first performed RNase H digestion of RNA pre-incubated without any oligonucleotide or with a control oligonucleotide that annealed with α -tubulin (another abundant transcript in *T. brucei*) did not affect the mobility of the m⁶A band (Fig. 2D). Next, we used an oligonucleotide that hybridized to the spliced leader (SL) sequence, a 39nt sequence that contains the mRNA cap and that is added to every mRNA by a trans-splicing reaction²³. RNase H digestion of RNA pre-incubated with the SL oligonucleotide showed no effect on m⁶A immunoblotting signal (Fig. 2D). This indicates that m⁶A is neither present in spliced leader sequence, nor in the mRNA cap structure. In contrast, when we used oligonucleotides VSG-A, VSG-B and VSG-C, which hybridized to three different unique sites in the VSG sequence (Fig. 2C), we observed that the major m⁶A band shifted, and in all three conditions, the 3' end fragment contained the entire m⁶A signal. Importantly, VSG-C oligonucleotide is adjacent the beginning of the poly(A) tail. Thus, the 3' fragment released upon RNase H digestion with VSG-C corresponds to the poly(A) tail of VSG mRNA. This fragment, which contains the entire m⁶A signal from the VSG transcript, is heterogeneous in length and shorter than 200 nt (Fig. 2D).

To further confirm that the 3' fragment released after incubation with VSG-C and RNase H corresponds to the VSG poly(A) tail, we performed RNase H digestion in RNA pre-incubated with a poly(T) oligonucleotide. Consistent with the results using VSG-C, the major band detected by m⁶A-antibody completely disappears, further supporting the idea that in bloodstream forms most m⁶A is present in the poly(A) tail of VSG mRNA. Interestingly, digestion of RNA hybridized with poly(T), also abolished the smear detected by m⁶A-antibody, indicating that m⁶A present in non-VSG transcripts is also most likely located in their poly(A) tails. Notably, a similar approach to digest poly(A) tails does not affect m⁶A levels in mammalian mRNA of HeLa cells¹³. Thus, this is the first demonstration that a poly(A) tail can harbour a modified nucleotide.

Our results show that although VSG mRNA is only 4-11% of total mRNA, it accounts for ~50% of cellular m⁶A, suggesting that VSG mRNA is preferentially enriched in m⁶A compared to other mRNAs. Based on the m⁶A frequency in the transcriptome and the enrichment in VSG, we estimate that there are nearly four m⁶A molecules per VSG mRNA. In contrast, among the non-VSG mRNAs, only one in five mRNAs are predicted to contain m⁶A.

Removing m⁶A precedes deadenylation and degradation of VSG transcript

The half-life of VSG transcript is 90-270 min, while the median mRNA half-life in trypanosomes is 13 min⁶. Given that removal of the poly(A) tail often precedes RNA degradation, we hypothesized that the presence of m⁶A in the poly(A) tail could account for this exceptional VSG mRNA stability.

We tracked m⁶A levels in VSG mRNA as it undergoes degradation in three independent conditions. We first inhibited transcription in bloodstream form parasites with actinomycin D (ActD) and, for the next 6 hours, we quantified the amount of VSG mRNA that remains (by qRT-PCR). We also measured the levels of m⁶A in VSG (by immunoblotting) and the length of the VSG poly(A) tail using

the Poly(A) Tail-Length Assay (PAT), which involves ligation of adaptors to the 3' end of poly(A) tails and two consecutive PCRs using *VSG*-specific forward primers (Fig. 3A). The amplified fragments contain part of the ORF, the 3'UTR of *VSG* transcript and the downstream poly(A) tail, whose size is variable between different transcript molecules.

VSG mRNA has previously been shown to exhibit biphasic decay: in the first hour after transcription blocking *VSG* mRNA levels remain high and, only in a second phase, do *VSG* mRNA levels decay exponentially^{9,24}. Consistent with these earlier findings, we detected no major changes in mRNA abundance during the first hour after actinomycin D treatment (lag phase, or first phase); however, afterwards *VSG* exhibited exponential decay (second phase) (Fig. 3B). During the one hour lag phase, the length of the *VSG* poly(A) tail was unchanged, but then it rapidly shortened during the second phase. This indicates that there is a specific time-dependent step that triggers the rapid shortening of the *VSG* poly(A) tail and the subsequent degradation of the *VSG* transcript. Immunoblotting revealed that the m⁶A levels also decreased, but strikingly the loss of m⁶A preceded the shortening of the poly(A) tail and subsequent mRNA decay (Fig. 3C). In fact, m⁶A levels decrease exponentially during the first hour after actinomycin D, taking around 35 min for total mRNA m⁶A levels to drop 50%, while *VSG* mRNA only reached half of the steady-state levels around 2hr (Fig. 3B). These results indicate that m⁶A is removed from *VSG* mRNA prior to the deadenylation of the poly(A) tail, which is quickly and immediately followed by degradation of the transcript.

When bloodstream form parasites undergo cellular differentiation to procyclic forms, *VSG* is downregulated as a consequence of decreased transcription and decreased mRNA stability⁹. To test whether m⁶A is also rapidly removed from *VSG* mRNA prior to its developmentally programmed degradation, we induced differentiation *in vitro* by adding cis-aconitate to the medium and changing the temperature to 27°C. Parasites were collected and total RNA was extracted in different time points. Quantitative qRT-PCR showed that the levels of *VSG* mRNA stayed stable for around one hour, which was followed by an exponential decay (Fig. 3D). Importantly, immunoblotting analysis showed that during parasite differentiation, m⁶A intensity in the *VSG* mRNA dropped faster than the *VSG*-mRNA levels, reaching half of the steady-state levels in 23 min (Fig. 3D-E). Thus, during parasite differentiation, we observed again that the removal of m⁶A precedes the loss of *VSG* mRNA levels.

In addition to differentiation, another trigger for *VSG* mRNA degradation is translation inhibition, which can be achieved by treating parasites with drugs such as puromycin²⁵. We treated bloodstream form parasites with puromycin and collected RNA samples for 4 hours. Consistent with previous studies, qRT-PCR revealed that *VSG* mRNA is actively degraded and it takes around 39 min to reach half of steady state levels (Extended Data Fig. S3). Immunoblotting revealed, once again, that m⁶A is removed earlier from the *VSG* transcript with a half-life of about 10 min (Extended Data Fig. S3).

Overall, these results show that in three independent conditions, m⁶A is removed from the *VSG* transcript earlier than the *VSG* transcript is deadenylated and degraded, suggesting that m⁶A may need to be removed from the *VSG* transcript before it can be degraded.

Figure 3. m⁶A is removed from VSG mRNA prior to its degradation.

a. Diagram of VSG2 mRNA transcript. Primers used for qRT-PCR are indicated in pink, primers used for PAT assay are indicated in dark blue and methylated adenosines of the poly(A) tail are indicated in light blue. **b.** Quantification of VSG2 transcript levels, m⁶A signal and the length of poly(A) tail after transcription halt by actinomycinD (ActD). Total RNA of bloodstream parasites was extracted after various time-points of ActD treatment. Values were normalized to 0 hr. Transcript levels were measured by qRT-PCR (pink), m⁶A levels were measured by immunoblotting signal (light blue) and the length of the poly(A) tail was measured by PAT assay (dark blue). **c.** Immunoblotting with anti-m⁶A antibody of bloodstream form total RNA extracted from parasites treated with actinomycin D for increasing times. 2 µg of total RNA were loaded per lane. Staining of rRNA with Methylene Blue confirmed equal loading. **d.** Quantification of VSG2 transcript levels, m⁶A signal and the length of poly(A) tail during parasite differentiation from bloodstream to procyclic forms. Total RNA was extracted at different time-points after inducing differentiation with cis-aconitate. Values were normalized to 0 hr. Same color code as in Panel B. **e.** Immunoblotting with anti-m⁶A antibody of parasites differentiating to procyclic forms. 2 µg of total RNA were loaded per lane. Staining of rRNA with methylene blue confirmed equal loading. (see also Extended Data Fig. S3)

Inclusion of m⁶A in *VSG* mRNA is dependent on *de novo* transcription

In most organisms, m⁶A is generated by methylation of adenosine residues within a specific consensus sequence by the METTL3 methyltransferase or its orthologs¹⁵. Given that in *T. brucei*, m⁶A is present in the poly(A) tail, a different mechanism is likely used. Indeed, trypanosomes lack a METTL3 ortholog²⁶, indicating that a different pathway would be required to acquire m⁶A in the poly(A) tail. To understand how m⁶A accumulates in the *VSG* mRNA, we used parasite differentiation as a natural inducible system of *VSG* downregulation. This process is reversible in the first two hours²⁷. Parasite differentiation was induced by adding cis-aconitate for 30 min (as described above, Fig. 3D), and then was washed away. As shown above, immunoblotting revealed that m⁶A was reduced after 30 min of cis-aconitate treatment (Fig. 4A-B, Fig. 3E). In contrast, when cells were allowed to recover for 1 hr in the absence of cis-aconitate or other drugs, we observed that the intensity of the m⁶A signal returned to normal levels (Fig. 4A-B). These results indicate that, if differentiation is halted and the levels of *VSG* mRNA are re-established (Extended Data Fig. S4), *VSG* m⁶A is quickly recovered.

To test if the recovery of m⁶A levels after cis-aconitate removal was due to *de novo* transcription, parasites were cultured in the presence of actinomycin D. We observed that the intensity of m⁶A in the *VSG* transcript was not recovered. Instead, the m⁶A levels decreased by ~20% (Fig. 4A-B). Overall, these results indicate that *de novo* transcription is required to re-establish m⁶A levels in *VSG* mRNA.

If m⁶A is included in *VSG* mRNA soon after transcription, and if it remains in the poly(A) tail until it gets degraded, we should be able to detect m⁶A in the nucleus and in the cytoplasm of the parasites. Immunofluorescence analysis with an antibody against m⁶A showed a punctate pattern both in the nucleus (20%) and cytoplasm (80%) (Fig. 4D-E). To confirm that this m⁶A signal originated from RNA, we incubated the fixed cells with nuclease P1 prior to the antibody staining, which specifically cleaves single-stranded RNA without any sequence-specific requirement. This treatment caused a marked reduction in the intensity of the m⁶A signal, indicating that the immunoreactivity of the m⁶A antibody derives from RNA, and not non-specific interactions with cellular proteins (Fig. 4C-D). As an additional control, we treated with actinomycin D for 2 hr prior to immunofluorescence analysis. This treatment is expected to result in reduced cellular mRNA levels. Immunostaining with the m⁶A antibody showed a drop in the intensity of the m⁶A signal by around 40% (Fig. 4D-E), which is similar to the reduction observed by immunoblotting (Fig. 3B-C). Overall, these data support the idea that the m⁶A immunostaining results likely reflect m⁶A in mRNA and not a non-specific binding of the antibody to the cells.

Figure 4. Inclusion of m⁶A in the VSG poly(A) tail depends of *de novo* transcription.

a. Experimental setup. Parasites were treated with cis-aconitate (CA) for 30 min, time at which the compound was washed away. Parasites were placed back in culture in 3 different conditions for an extra hour: in the presence of cis-aconitate, without cis-aconitate, without cis-aconitate but with transcription inhibitor actinomycin D (ActD). Labels 1-5 indicate the conditions at which parasites were collected for Immunoblotting analysis (panel B). **b.** Immunoblot with anti-m⁶A antibody of total RNA from bloodstream parasites collected at each of the 5 labelled conditions (panel A). **c.** Quantification of Immunoblotting in panel A. All levels were normalized to time point 0 hr. **d.** Immunofluorescence analysis showing m⁶A localization in mammalian BSF. Parasites were treated with Nuclease P1 (NP1) or actinomycin D (ActD) to confirm signal-specificity. Nuclei were stained with Hoechst. Arrow in top row points to m⁶A signal in the nucleus. Arrow in bottom panel points to weak m⁶A signal; scale bars, 4 μm. **e.** Quantification of mean fluorescence intensity (MFI) levels of m⁶A in untreated BSF, nuclease P1 (NP1)-treated BSF, and actinomycin D (ActD)-treated BSF. Raw MFIs were obtained, the average of the untreated BSF equalled to 100%, and all other values normalized to 100%. Error bars indicate SEM. Results shown are the mean of *n* = 2 independent experiments, and *n* = 500 parasites per condition. **f.** Quantification of the proportion of m⁶A signal in nucleus and cytoplasm across 500 parasites (untreated BSF). The proportion was calculated by segmentation dividing the parasite body and nucleus, and quantifying fluorescence intensity in each segment. Error bars indicate SEM. DIC, differential interference contrast.

(see also Extended Data Fig. S4)

Inclusion of m⁶A in VSG poly(A) tail is dependent on neighboring cis-acting motif

m⁶A is added to the VSG mRNA poly(A) tail soon after transcription, probably still in the nucleus. m⁶A is not simply targeted to all poly(A) tails in the cell since, if this were the case, all mRNAs would be methylated and VSG methylation would only account for 4-11% of total cellular m⁶A. We therefore asked how the VSG poly(A) tail is selected for preferential enrichment of m⁶A. It has been previously shown that each VSG gene contains a conserved 16-mer motif (5'-TGATATATTTTAACAC-3') in the 3'UTR adjacent to the poly(A) tail that is necessary for VSG mRNA stability⁷. It has been proposed that a currently unknown RNA-binding protein may bind this motif and stabilize the transcript by an unknown mechanism⁷. Here, we hypothesized that this 16-mer motif may act *in cis* to promote inclusion of m⁶A of the adjacent poly(A) tail.

To test the function of the 16-mer motif, we could not simply mutagenize it because this would lead to an irreversible loss of VSG protein, which is lethal for the parasites⁷. Therefore, we created two reporter cell-lines, in which a second VSG gene (*VSG117*) was introduced in the active BES, from where *VSG2* is normally transcribed (Fig. 5A). As a result, these reporter cell-lines are VSG double-expressors, i.e. they simultaneously express *VSG2* and *VSG117* at the cell surface. In the cell line designated "VSG double expressor 1", or "DE1", the *VSG117* gene contains the endogenous *VSG2* 3'UTR which harbors the 16-mer motif. In the second cell-line, "VSG double expressor 2", or "DE2", *VSG117* contains the same 3'UTR, except that the sequence of the 16-mer motif was scrambled (5'-GTTATACAAAACCTTTT-3') (Fig. 5A). As has been previously reported, the transcript levels of *VSG2* and *VSG117* are dependent on each other and are dependent on the presence of the 16-mer motif⁷. Quantitative RT-PCR analysis showed that the two VSGs have roughly the same levels in DE1 cell-line. However, in DE2, *VSG117* transcript is about 7-fold less abundant than *VSG2*. (Fig. 5B, 5D).

To test whether the 16-mer motif is required for inclusion of m⁶A in VSG poly(A) tails, we performed m⁶A immunoblotting of cellular RNA obtained from the two double-expressor cell lines. Given that *VSG2* and *VSG117* transcripts have similar sizes (~1.8 kb), we used RNase H to selectively cleave *VSG2* before resolving the RNA on gel. *VSG2* cleavage was performed by incubating the total RNA sample with an oligonucleotide that hybridizes to the *VSG2* open reading frame, followed by incubation with RNase H (as described in Fig. 2). As expected, the *VSG2*-m⁶A-containing fragment is smaller and runs faster on gel (Fig. 5C). An "m⁶A index" was calculated by dividing the relative intensity of m⁶A in each VSG band (Fig. 5C) by the corresponding relative transcript levels measured by qRT-PCR (Fig. 5B). A low m⁶A index indicates a given transcript has fewer modified nucleotides (Fig. 5D).

Figure 5. Conserved VSG 16-mer motif is required for inclusion of m⁶A in adjacent poly(A) tail.

a. Diagram of 16-mer motif VSG double-expressor (DE) cell-lines. *VSG117* was inserted immediately downstream of the promoter of the active bloodstream expression site, which naturally contains *VSG2* at the telomeric end. In VSG double expressor 16-mer^{WT} cell-line, *VSG117* contains its endogenous 3'UTR with the conserved 16-mer motif (sequence shown in blue). In VSG double expressor 16-mer^{MUT} cell-line, the 16-mer motif was scrambled (sequence shown in orange). **b.** Transcript levels of *VSG117* and *VSG2* transcripts measured by qRT-PCR in both reporter cell-lines. Levels were normalized to transcript levels in cell-lines expressing only *VSG2* or only *VSG117*. **c.** Immunoblot with anti-m⁶A antibody of mRNA from VSG double-expressor cell-lines. RNase H digestion of *VSG2* mRNA was used to resolve *VSG2* and *VSG117* transcripts. Different quantities of the same VSG double expressor 16-mer^{WT} cell-line was loaded in two separate lanes (50ng and 12.5ng) to show that the *VSG117* band is detectable in both conditions. **d.** m⁶A index calculated as the ratio of m⁶A intensity and mRNA levels, measured in panels c. and b., respectively. und., undetectable. # intensities measured in lane 3 of Figure 5C (see also Extended Data Fig. S5)

d

Cell-line	VSG/ 3' UTR	m ⁶ A intensity (immunoblot)	mRNA (qPCR)	m ⁶ A index (AU)
DE 1	VSG117 16-mer ^{WT}	8.2 (2.1) #	0.42	19.6
	VSG2 16-mer ^{WT}	35.2 (8.5) #	0.50	70.3
DE 2	VSG117 16-mer ^{MUT}	und.	0.08	und.
	VSG2 16-mer ^{WT}	110.7	0.78	141.9

Whenever the 3'UTR of *VSG* transcripts contain a 16-mer^{WT} (*VSG*s with a blue box in Fig. 5A), *VSG* m⁶A bands are detectable by immunoblot and the m⁶A index varies between 20-140 arbitrary units. In contrast, when the 16-mer motif is mutagenized (*VSG117* with orange box in Fig. 5A), the *VSG* m⁶A is undetectable (Fig. 5C), and the m⁶A index therefore is too low to calculate. These results indicate that the motif is required for inclusion of m⁶A in the *VSG* transcript.

In contrast, if the 16-mer motif played no role in m⁶A inclusion, the *VSG117* m⁶A index would be identical in both cell-lines (DE1 and DE2), i.e. around 20. Given that the qRT-PCR quantifications showed the relative intensity of *VSG117* 16-mer^{MUT} is ~0.10 (Fig. 5B), the predicted intensity of the *VSG117* 16-mer^{MUT} m⁶A band would have been 20 x 0.10 = 2.0 arbitrary units. To be sure that a band with this level of m⁶A would be detected on an immunoblot, we ran a more diluted DE1 RNA sample in lane 3 (Fig. 5C). The intensity of the *VSG117* 16-mer^{WT} band is 2.1 arbitrary units (Fig. 5C and 5D), and it is easily detected in the immunoblot. Given that we could not detect any band corresponding to a putative methylated *VSG117* 16-mer^{MUT} in DE2 (even after over exposure of the immunoblot, Extended Data Fig. S5), we conclude that the *VSG* conserved 16-mer motif is necessary for inclusion of m⁶A in the *VSG* poly(A) tail.

m⁶A is required for *VSG* mRNA stability

The unusual localization of m⁶A in the poly(A) tail, and the lack of a METTL3 ortholog, suggests that the underlying biochemistry of m⁶A formation in trypanosomes is different from what has been described in other eukaryotes. Given that, at this stage the mechanism of m⁶A formation in the poly(A) tail is unknown and therefore cannot be directly blocked, we used the genetic mutants of the 16-mer conserved motif to enquire about the function of m⁶A in *VSG* mRNA.

To test the role of the 16-mer motif on poly(A) length on mRNA stability, we measured *VSG* mRNA stability in 16-mer^{WT} and 16-mer^{MUT} cell-lines. *VSG* mRNA half-life was measured by blocking transcription for 1 hr with actinomycin D (the duration of the lag phase during *VSG* mRNA decay) and the levels of *VSG* mRNA were followed by qRT-PCR. PAT assay clearly shows that, when the *VSG117* transcript contains the 16-mer motif (16-mer^{WT} cell-line), the length of the *VSG117* poly(A) tail is stable for 1 hr (Fig. 6A-B). In contrast, *VSG117* transcripts containing a scrambled 16-mer motif exhibited very rapid shortening of the poly(A) tail. In this case, there was no detectable lag phase—instead, the length of the poly(A) tail was reduced to 25% of its original length after just 15 min, and was undetectable after 1 hr (Fig. 6A-B). Consistent with the fast kinetics of poly(A) deadenylation, in the absence of an intact 16-mer motif, *VSG117* transcript levels decayed very rapidly with a half-life of ~20 min (Fig. 6B).

Overall, these experiments show that when the *VSG* conserved 16-mer motif is mutated and the m⁶A is lost, the *VSG* transcript is no longer stable and exhibits rapid poly(A) deadenylation and a marked reduction of mRNA stability.

Figure 6. VSG 16-mer motif delays poly(A) tail deadenylation.

a. The length of the VSG poly(A) tail was measured using Poly(A) tailing (PAT) assay. Specific primers confer specificity to the transcript being analysed. WT and Mut-16-mer cell-lines were compared. A0 corresponds to the minimum length amplified by PAT and it comprises the end of the VSG open reading frame and the whole 3'UTR. **b.** Quantification of VSG17 transcript levels and the length of poly(A) tail after transcription halt by actinomycin D. Total RNA of bloodstream parasites was extracted after the indicate times. Values were normalized to 0 hr. Transcript levels were measured by qRT-PCR (pink) and the length of the poly(A) tail was measured by PAT assay (dark blue).

Discussion

In this work we report the identification and the function of the first RNA epitranscriptomic modification in the poly(A) tail of mRNA. We show that the stability and abundance of VSG transcripts stem from a novel mechanism in which the presence of m⁶A in the poly(A) tail inhibits RNA degradation, probably by blocking deadenylation. We also show that m⁶A is regulated by processes that induce destabilization and degradation of VSG mRNA such as cellular differentiation.

The classic function of a poly(A) tail is to keep mRNAs from being degraded and to promote translation. Poly(A)-binding proteins (PABPs) bind the poly(A) tail and stimulate mRNA translation by interaction with translation initiation factors²⁸. Removal of the poly(A) tail by deadenylase complexes (e.g. Ccr4-Not complex) allow the unprotected mRNAs to enter in the 5'→3' or 3'→5' degradation pathways^{29,30}. In this report, we identified a novel mechanism by which a poly(A) tail contributes to mRNA stability. We found that the poly(A) tail of VSG, a transcript that represents 4-11% of mRNAs from *T. brucei* bloodstream forms, contains half of the m⁶A present in the cell. Our estimates suggest that each VSG poly(A) tail has around 4 modified adenosines. When we measured VSG mRNA decay rates by treating with transcription-blocking drugs, we found that m⁶A is removed from the VSG poly(A) tail before the tail is deadenylated and mRNA is degraded, raising the possibility that m⁶A normally prevents these processes. A similar observation was made during parasite differentiation. The removal of m⁶A may therefore be the step that initiates deadenylation and mRNA decay. To test this idea, we removed a 16-mer motif in the 3'UTR, which we find is necessary for the inclusion of m⁶A in the VSG poly(A)

tail. When m⁶A levels in VSG mRNA become undetectable, by mutating this sequence element, the VSG mRNA exhibits rapid deadenylation and mRNA decay. Overall these data support the idea that m⁶A acts as a stabilizer of the VSG mRNA.

The presence of m⁶A in the poly(A) tail is so far unique to trypanosomes. In other eukaryotes, m⁶A has been mainly detected by m⁶A mapping approaches around the stop codon and 3' UTR, where it plays a role in mRNA stability and translation¹⁵. A mapping study was recently published in *T. brucei* in which the authors conclude that m⁶A localizes in internal regions of transcripts³¹. m⁶A was not reported to be in the poly(A) tail in this previous study. However, m⁶A mapping relies on aligning m⁶A-containing RNA fragments to genomic sequence. Since the poly(A) sequence is not encoded in the genome, and m⁶A-containing fragment from the poly(A) tail would not be mappable and therefore not detected in this or any other previous m⁶A mapping study.

It remains unclear how m⁶A gets into the poly(A) tail. The presence of m⁶A in the poly(A) tail suggests that an unusual RNA-methyltransferase will directly or indirectly bind to the 16-mer motif and methylate adenosines that are either adjacent to the 16-mer motif or become more proximal via a loop-like conformation of the poly(A) tail. This would explain why orthologs of the canonical METTL3 enzyme does not exist in the trypanosome genome²⁶. Unfortunately, previous efforts from other labs have been unsuccessful at identifying proteins that specifically bind to the 16-mer motif^{7,32}. An alternative mechanism would be if m⁶A is incorporated into the poly(A) tail while polymerisation takes place. If this was true, there should be m⁶ATP inside the cell. Unbiased metabolomics³³ did not support the existence of m⁶ATP, although studies specifically focused on detecting this nucleotide would be required to completely disprove this model.

Deadenylation is the first step in the main mRNA decay pathway in eukaryotes³⁴. *T. brucei* is not an exception²³. In this study we showed that m⁶A seems to protect the poly(A) tail from deadenylation. The molecular mechanism behind this stabilizing effect is unknown. It is possible that the deadenylases are inefficient on a methylated poly(A) tail. There is structural and biochemical evidence that poly(A) tails adopt a tertiary structure that facilitates the recognition by some deadenylases (CAF1 and Pan2)³⁵. When a poly(A) tail contains m⁶A, just like when it contains guanosines, the tertiary structure may be not properly assembled and deadenylase activity is inhibited. In this model, a putative demethylase may be required to remove the methyl group and only then poly(A) tail would be deadenylated. Alternatively, the stabilizing effect of m⁶A could result from recruitment of a specific RNA-binding protein, that prevents the poly(A) tail from being deadenylated.

T. brucei has around 2000 VSG genes, but only one is actively transcribed at a given time². By a process of antigenic variation, parasites evade the host immune response by changing an old VSG surface coat to a new VSG coat that is antigenically distinct. m⁶A may be removed from VSG mRNA, facilitating the switch from the old VSG mRNA, so that it can be more rapidly replaced by a new VSG coat protein. Since m⁶A stabilizes the VSG mRNA, it will also be important to determine whether inability to synthesize m⁶A in poly(A) tails results in more frequent switching to new VSG coat proteins. The role of m⁶A in differentiation

remains to be established but it is possible that a delayed removal of VSG would interfere with the interaction of the parasite with the midgut wall.

The Rudenko lab has proposed that the maximal amount of VSG mRNA per cell is dependent on a post-transcriptional limiting factor dependent on the presence of the 16-mer motif ⁷. We propose that this limiting factor is the rate of inclusion of m⁶A in the poly(A) tails. When the 16-mer motif is present in both VSG genes, both get partially methylated and their abundance is reduced to about half of a single-VSG expressor; however, when the 16-mer motif is absent from one of the VSGs, the second VSG is more methylated and the transcripts become more abundant.

As far as we know, our work describes the first RNA modification in poly(A) tails. We show that m⁶A is present in the poly(A) tail of *T. brucei* mRNAs, it is enriched in the most abundant transcript (VSG), and that m⁶A acts as a protecting factor stabilizing VSG transcripts. It will be important for future studies to identify the enzymes and proteins involved in adding, reading, or removing this RNA modification. Given the importance of VSG regulation for chronic infection and parasite transmission, drug targeting such enzymes is expected to result in an important loss of parasite virulence. Understanding these regulatory epitranscriptomic processes may open up possibilities for developing therapeutic strategies to treat sleepiness sickness.

References

1. Franco, J. R., Simarro, P. P., Diarra, A., Ruiz-Postigo, J. A. & Jannin, J. G. The journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy. *Parasitology* **141**, 748-760 (2014).
2. Horn, D. Antigenic variation in African trypanosomes. *Mol Biochem Parasitol* **195**, 123-129 (2014).
3. Cross, G. A. Identification, purification and properties of clone-specific glycoprotein antigens constituting the surface coat of *Trypanosoma brucei*. *Parasitology* **71**, 393-417 (1975).
4. Nilsson, D. *et al.* Spliced leader trapping reveals widespread alternative splicing patterns in the highly dynamic transcriptome of *Trypanosoma brucei*. *PLoS Pathog* **6**, (2010).
5. Kraus, A. J., Brink, B. G. & Siegel, T. N. Efficient and specific oligo-based depletion of rRNA. *Sci Rep* **9**, 12281 (2019).
6. Fadda, A. *et al.* Transcriptome-wide analysis of trypanosome mRNA decay reveals complex degradation kinetics and suggests a role for co-transcriptional degradation in determining mRNA levels. *Mol Microbiol* **94**, 307-326 (2014).
7. Ridewood, S. *et al.* The role of genomic location and flanking 3'UTR in the generation of functional levels of variant surface glycoprotein in *Trypanosoma brucei*. *Mol Microbiol* **106**, 614-634 (2017).
8. Roditi, I. *et al.* Procyclin gene expression and loss of the variant surface glycoprotein during differentiation of *Trypanosoma brucei*. *J Cell Biol* **108**, 737-746 (1989).
9. Ehlers, B., Czichos, J. & Overath, P. RNA turnover in *Trypanosoma brucei*. *Mol Cell Biol* **7**, 1242-1249 (1987).

10. Matthews, K. R. The developmental cell biology of *Trypanosoma brucei*. *J Cell Sci* **118**, 283-290 (2005).
11. Wei, C. M., Gershowitz, A. & Moss, B. Methylated nucleotides block 5' terminus of HeLa cell messenger RNA. *Cell* **4**, 379-386 (1975).
12. Perry, R. P., Kelley, D. E., Friderici, K. & Rottman, F. The methylated constituents of L cell messenger RNA: evidence for an unusual cluster at the 5' terminus. *Cell* **4**, 387-394 (1975).
13. Meyer, K. D. *et al.* Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell* **149**, 1635-1646 (2012).
14. Dominissini, D. *et al.* Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. *Nature* **485**, 201-206 (2012).
15. Zaccara, S., Ries, R. J. & Jaffrey, S. R. Reading, writing and erasing mRNA methylation. *Nat Rev Mol Cell Biol* **20**, 608-624 (2019).
16. Freistadt, M. S., Cross, G. A. & Robertson, H. D. Discontinuously synthesized mRNA from *Trypanosoma brucei* contains the highly methylated 5' cap structure, m7GpppA*A*C(2'-O)mU*A. *J Biol Chem* **263**, 15071-15075 (1988).
17. Bangs, J. D., Crain, P. F., Hashizume, T., McCloskey, J. A. & Boothroyd, J. C. Mass spectrometry of mRNA cap 4 from trypanosomatids reveals two novel nucleosides. *J Biol Chem* **267**, 9805-9815 (1992).
18. Perry, K. L., Watkins, K. P. & Agabian, N. Trypanosome mRNAs have unusual "cap 4" structures acquired by addition of a spliced leader. *Proc Natl Acad Sci U S A* **84**, 8190-8194 (1987).
19. Hauenschild, R. *et al.* The reverse transcription signature of N-1-methyladenosine in RNA-Seq is sequence dependent. *Nucleic Acids Res* **43**, 9950-9964 (2015).
20. Boccaletto, P. *et al.* MODOMICS: a database of RNA modification pathways. 2017 update. *Nucleic Acids Res* **46**, D303-D307 (2018).
21. Siegel, T. N., Gunasekera, K., Cross, G. A. & Ochsenreiter, T. Gene expression in *Trypanosoma brucei*: lessons from high-throughput RNA sequencing. *Trends Parasitol* **27**, 434-441 (2011).
22. Butter, F. *et al.* Comparative proteomics of two life cycle stages of stable isotope-labeled *Trypanosoma brucei* reveals novel components of the parasite's host adaptation machinery. *Mol Cell Proteomics* **12**, 172-179 (2013).
23. Clayton, C. E. Regulation of gene expression in trypanosomatids: living with polycistronic transcription. *Open Biology* **9**, 190072 (2019).
24. Hoek, M., Zanders, T. & Cross, G. A. M. *Trypanosoma brucei* expression-site-associated-gene 8 protein interacts with a *Pumilio* family protein. *Mol. Biochem. Parasitol.* **120**, 269-283 (2002).
25. Ehlers, B., Czichos, J. & Overath, P. Repression and reactivation of the variant surface glycoprotein gene in *Trypanosoma brucei*. *FEBS Lett* **225**, 53-58 (1987).
26. Iyer, L. M., Zhang, D. & Aravind, L. Adenine methylation in eukaryotes: Apprehending the complex evolutionary history and functional potential of an epigenetic modification. *Bioessays* **38**, 27-40 (2016).
27. Domingo-Sananes, M. R., Szoor, B., Ferguson, M. A., Urbaniak, M. D. & Matthews, K. R. Molecular control of irreversible bistability during trypanosome developmental commitment. *J Cell Biol* **211**, 455-468 (2015).
28. Gallie, D. R. The role of the poly(A) binding protein in the assembly of the Cap-binding complex during translation initiation in plants. *Translation (Austin)* **2**, e959378 (2014).
29. Garneau, N. L., Wilusz, J. & Wilusz, C. J. The highways and byways of mRNA decay. *Nat Rev Mol Cell Biol* **8**, 113-126 (2007).
30. Chen, C. Y. & Shyu, A. B. Mechanisms of deadenylation-dependent decay. *Wiley Interdiscip Rev RNA* **2**, 167-183 (2011).

31. Liu, L. *et al.* Differential m6A methylomes between two major life stages allows potential regulations in *Trypanosoma brucei*. *Biochem Biophys Res Commun* **508**, 1286-1290 (2019).
32. Klein, C., Terrao, M., Inchaustegui Gil, D. & Clayton, C. Polysomes of *Trypanosoma brucei*: Association with Initiation Factors and RNA-Binding Proteins. *PLoS One* **10**, e0135973 (2015).
33. Creek, D. J. *et al.* Probing the metabolic network in bloodstream-form *Trypanosoma brucei* using untargeted metabolomics with stable isotope labelled glucose. *PLoS Pathog* **11**, e1004689 (2015).
34. Decker, C. J. & Parker, R. A turnover pathway for both stable and unstable mRNAs in yeast: evidence for a requirement for deadenylation. *Genes Dev* **7**, 1632-1643 (1993).
35. Tang, T. T. L., Stowell, J. A. W., Hill, C. H. & Passmore, L. A. The intrinsic structure of poly(A) RNA determines the specificity of Pan2 and Caf1 deadenylases. *Nat Struct Mol Biol* **26**, 433-442 (2019).
36. Wirtz, E., Leal, S., Ochatt, C. & Cross, G. A. M. A tightly regulated inducible expression system for dominant negative approaches in *Trypanosoma brucei*. *Molecular & Biochemical Parasitology* **99**, 89-101 (1999).
37. Hirumi, H. & Hirumi, K. Continuous cultivation of *Trypanosoma brucei* blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. *J Parasitol* **75**, 985-989 (1989).
38. Vassella, E. & Boshart, M. High molecular mass agarose matrix supports growth of bloodstream forms of pleomorphic *Trypanosoma brucei* strains in axenic culture. *Mol Biochem Parasitol* **82**, 91-105 (1996).
39. Czichos, J., Nonnengaesser, C. & Overath, P. *Trypanosoma brucei*: cis-aconitate and temperature reduction as triggers of synchronous transformation of bloodstream to procyclic trypomastigotes in vitro. *Exp Parasitol* **62**, 283-291 (1986).
40. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* **29**, e45 (2001).
41. Haanstra, J. R. *et al.* Control and regulation of gene expression: quantitative analysis of the expression of phosphoglycerate kinase in bloodstream form *Trypanosoma brucei*. *J Biol Chem* **283**, 2495-2507 (2008).
42. Berriman, M. *et al.* The genome of the African trypanosome *Trypanosoma brucei*. *Science* **309**, 416-422 (2005).
43. Koch, H., Raabe, M., Urlaub, H., Bindereif, A. & Preußner, C. The polyadenylation complex of *Trypanosoma brucei*: Characterization of the functional poly(A) polymerase. *RNA Biology* **13**, 221-231 (2016).

Supplementary information

Figures S1 to S5
Tables S1 to S3

Acknowledgments

The authors thank support from Howard Hughes Medical Institute International Early Career Scientist Program [55007419] and European Molecular Biology Organization Installation grant [2151]. This work was also partially supported by ONEIDA project (LISBOA-01-0145-FEDER-016417) co-funded by FEEI - "Fundos Europeus Estruturais e de Investimento" from "Programa Operacional Regional Lisboa 2020" and by national funds from FCT - "Fundação para a Ciência e a Tecnologia". Researchers were funded by individual fellowships from Fundação para a Ciência e Tecnologia (PD/BD/105838/2014 to IJV, SFRH/BD/80718/2011 to FAB); a Novartis Foundation for Biomedical-Biological research to JPM; a Human Frontier Science Programme long term postdoctoral fellowship to MDN (LT000047/2019); the GlycoPar Marie Curie Initial Training Network (GA 608295) to JAR. LMF is an Investigator of the Fundação para a Ciência e Tecnologia. Publication of this work was also funded LISBOA-01-0145-FEDER-007391, project cofunded by FEDER, through POR Lisboa 2020 - Programa Operacional Regional de Lisboa, PORTUGAL 2020, and Fundação para a Ciência e a Tecnologia. We are grateful to Jane Thomas-Oates and Ed Bergstrom (York University, Centre of Excellence in Mass Spectrometry, Department of Chemistry) for the Mass-spectrometry analysis; Antonio Temudo, Ana Nascimento and Aida Lima for bio-imaging assistance; Ana Pena and members of Figueiredo and Jeffrey labs for helpful discussions.

Author contributions

I.J.V., J.P.M., M.D.N and J.A.R performed experiments.
I.J.V., J.P.M., M.D.N, J.A.R, F.A.B, S.R.J and L.M.F planned experiments & analyzed data.
I.J.V., F.A.B., J.A.R., S.R.J and L.M.F conceived study.
I.J.V., S.R.J and L.M.F wrote manuscript, with contributions of all remaining authors.

Competing interests

The authors do not have conflicts of interest.

Methods

Cell culture and cell-lines

Trypanosoma brucei bloodstream form (BSF) parasites (EATRO 1125 AnTat1.1 90:13, and Lister 427 antigenic type MiTat 1.2, clone 221a, Single Marker (SM) cell line³⁶ were cultured in HMI11, supplemented with 10% Fetal Bovine Serum, at 37°C in 5% CO₂³⁷. Procyclic forms were cultured in DTM supplemented with 10% Fetal Bovine Serum at 27°C^{38,39}. Parasites were routinely grown in the presence of the selectable drugs: neomycin 2.5 µg·mL⁻¹, hygromycin 5 µg·mL⁻¹ for EATRO 1125 AnTat1.1 90:13 and neomycin 2.5 µg·mL⁻¹ for SM. Transcription was inhibited by treating parasites with 5 µg·mL⁻¹ of actinomycin D (Sigma A4262). Differentiation of slender into stumpy forms was induced by adding 6 mM cis-aconitate (Sigma A3412) to the culture and dropping temperature to 27°C. Protein translation was inhibited with 50 µg·mL⁻¹ of puromycin (ant-pr-1, Invivogen).

Parasite cell lines were generated by transfection of *T. brucei* SM with plasmid p221- purVSG117UTR (Addgene plasmid 59732) or with p221- purVSG117UTRmut (Addgene plasmid 59732,⁷). The 16-mer mutagenized motif was introduced in a primer that was used to PCR amplify p221-purVSG117UTR plasmid. Amplification was performed with Phusion High-Fidelity DNA polymerase (ThermoScientific). After elimination of original plasmid template by digestion with *DpnI* (NEB R0176), amplification products were transformed into *E. coli* JM109 (Promega L2005). Plasmids were isolated and purified from bacteria, digested with *NotI*-HF (NEB R3189) and *XhoI* (NEB R0146), ethanol precipitated and transfected. Transfections were made with the AMAXA nucleofactor II (Lonza Bioscience), program X-001, using transfection buffer (90 mM sodium phosphate, 5 mM potassium chloride, 0.15 mM calcium chloride, 50 mM HEPES, pH 7.3). After overnight growth, transfected clones were selected by adding 1 µg·mL⁻¹ puromycin.

LC-MS/MS

RNA samples were digested with nuclease P1 (sigma N8630, 1 U per 50 ng) for 2h at 37°C in buffer (2.5 mM ZnCl₂, 40 mM NH₄Ac, pH 5.3). After dephosphorylation was done by addition of 10 U of Antarctic phosphatase (NEB M0289) in the buffer provided for 2h at 37°C. Digested samples were diluted in mili-Q water (10 ng/µL) and filtered with Microcon – 30 kDa. Chromatographic separation was performed on a liquid chromatography system Ultimate 3000 RSLCnano (Thermo Fisher Scientific). Column – CORTECS® P3 (3 mm x 150 mm, 2.7 µm particle size, Waters Corporation). Mobile phase consisted of water containing 0.1% formic acid (A) and methanol containing 0.1% formic acid (B). The used elution gradient (A:B, v/v) was as follows: 100:0 for 2 min; 100:75 at 4 min; 75:30 at 9 min; 30:70 at 12 min; 0:100 at 15 min; 0:100 isocratic elution from 15.5 to 20 min. Samples were separated by liquid chromatography (column Waters CORTECS T3 2.7µ 3.0 x 150 mm, Gradient with mobile phase A of water 0,1% formic acid and mobile phase B of methanol 0,1% formic acid.) and analyzed in triple quadrupole Thermo Scientific TSQ Endura mass spectrometer

with electrospray ionization in positive mode, and followed by multiple reaction monitoring. The ion mass transitions for m⁶A was 282,090>[150,059-150,061] and for adenosine was 268,061>[136,110-136,112]. Calibration curves were done with chemical standards and area under the curve (peak) integrated. To calculate m⁶A to adenosine molar ratio, m⁶A and adenosine amounts were calculated in the same sample injection. The ion mass transition of other modified nucleosides are shown in Supplementary Table 1.

RNA isolation and handling

RNA was extracted from bloodstream and procyclic form parasites with TRIzol (Invitrogen). 10-100 million parasites were lysed in 1 mL of TRIzol. RNA was isolated according to the instructions of the manufacturer. RNA was treated with DNase I (NEB M0303) (1 U per 2.5 µg of RNA) for 20 min. Reaction was inactivated by adding 5 mM EDTA and heating to 75°C for 10 min. Purification of mRNA was performed with NEBNext mRNA isolation module (NEB E7490), following the manufacturer's instructions. The RNA that did not bind to the poly(T)-beads was ethanol precipitated and saved. This RNA fraction was used as A- RNA.

cDNA was generated using a SuperScript II Reverse Transcriptase (Invitrogen 18064-014), using random hexamers, according to manufacturer's protocol. Quantitative PCR (qPCR) was performed using SYBR Green PCR Master Mix (Applied Biosystems 4368702 Power SYBR). Primer efficiencies were determined using standard curves. Relative quantification was performed based on the CT (cycle threshold) value and the method of Pfaffl⁴⁰. Amplifications were normalized to 18S ribosomal RNA transcript. Primers are indicated in Supplementary Table 2.

m⁶A Immunoblotting

DNase I-treated RNA samples were suspended in formaldehyde loading buffer (30% formamide, 1,2 M formaldehyde, 1X MOPS buffer), denatured by heating to 70°C for 5 min and immediately transferred to ice. 2 µg of total RNA or 50 ng of mRNA were typically loaded per lane. Samples were resolved on a denaturing agarose gel (1.4% agarose, 2,2 M formaldehyde, 1X Mops buffer) for 1 h at 100 V at 4°C. RNA was transferred to a nylon membrane (GE Healthcare Amersham Hybond-N+) by downward transfer with 10X SSC buffer (1,5 M NaCl 150 mM sodium citrate, pH 7.0) for 4-5 h. RNA was UV-crosslinked to the membrane with a Stratalinker 2400 crosslinker (120 mJ cm⁻²). Membranes were stained with 0.02% methylene blue (Sigma M9140, diluted in 0,3 M sodium acetate pH 5.5) for 5 min and washed in RNase free water. After imaging, methylene blue was removed by incubation in de-staining solution (0,2X SSC 1% SDS) and washed 3 times in PBST (1X PBS pH 7.4 with 0,1% tween20). Nylon membranes were blocked by incubation in 5% skimmed milk in PBST for 1 h and then incubated overnight with 1µg/mL rabbit anti-m⁶A antibody (Abcam ab151230, 1:1000 in 2.5% skimmed milk in PBST) at 4°C. Membranes were washed in PBST three times, 10 min each, and then incubated with HRP-conjugated donkey anti-rabbit IgG (GE Healthcare, NA934), diluted 1: 2500 in 2,5% skimmed milk in PBST for 1 h at room temperature. Membranes were washed in PBST, three times, 10 min each and signal developed with Western

Lightning Plus-ECL, Enhanced Chemiluminescence Substrate kit (PerkinElmer ref. NEL103E001EA). The percentage of m⁶A in the main “band” co-migrating with the 2 kb molecular weight standard was measured by the intensity of the “band” divided by the signal intensity of the whole lane.

Estimation of m⁶A per VSG mRNA.

The number of m⁶A per VSG mRNA molecule was estimated based on the enrichment of m⁶A 1) in the VSG transcript (0,06%), 2) on the fraction of m⁶A present in VSG mRNA (0,50) and 3) on previously quantified parameters (detailed below). The number of mRNAs per *T. brucei* bloodstream forms cell is 20 000⁴¹. The number of VSG mRNAs per cell is 1000⁴¹ (assuming that correspond to 5% of the mRNA). The average mRNA length is 2000 nt⁴². The approximate length of the poly(A) tail is 100 nt⁴³. The approximate frequency of adenosine in the transcriptome is 0,25.

The number of adenosines per mRNA molecule correspond to:

$$\text{Number of adenosines (An)} = (\text{length of mRNA} \times \text{frequency of adenosine}) + \text{poly(A) tail}$$

$$An = (2000 \times 0,25) + 100 \leftrightarrow An = 600 \text{ As}$$

The total number of adenosines in a bloodstream forms cell correspond to:

$$An \text{ in bloodstream forms} = \text{mRNAs per cell} \times An \text{ per mRNA}$$

$$An \text{ in BSF} = 20\,000 \times 600 \leftrightarrow An \text{ in BSF} = 12\,000\,000 \text{ As}$$

The amount of m⁶A per cell in mRNA is:

$$m^6A \text{ in bloodstream forms} = (\text{adenosines per cell} \times \text{Frequency of m}^6A \text{ in mRNA (\%)}) /$$

100

$$m^6A \text{ in BSF} = (12 \cdot 10^6 \times 0,006) / 100 \leftrightarrow m^6A \text{ in BSF} = 7200$$

The amount of m⁶A in VSG mRNA molecules correspond to:

$$m^6A \text{ in VSG mRNA} = m^6A \text{ in bloodstream forms} \times \text{Fraction of m}^6A \text{ in VSG mRNA}$$

$$m^6A \text{ in VSG} = 7200 \times 0,5 \leftrightarrow m^6A \text{ in VSG} = 3600 \text{ m}^6A\text{s}$$

The amount of m⁶A per VSG mRNA molecule correspond to:

$$m^6A \text{ per VSG} = m^6A \text{ in VSG} / \text{VSG mRNA copies}$$

$$m^6A \text{ per VSG} = 3600 / 1000 \leftrightarrow m^6A \text{ per VSG} = 3,6 \sim 4 \text{ m}^6A \text{ per VSG mRNA}$$

Therefore, every VSG mRNA molecule harbors around 4 m⁶A per molecule.

Following the same logic, the amount of m⁶A distributed in the non VSG mRNAs correspond to:

$$m^6A \text{ per non-VSG} = m^6A \text{ in non-VSG} / \text{non-VSG mRNA copies}$$

$$m^6A \text{ per non VSG} = 3600 / 19\,000 \leftrightarrow m^6A \text{ per non VSG} = 0,19 \sim 0,2 \text{ m}^6A \text{ per non VSG mRNA}$$

Therefore, in the non-VSG transcriptome there are around 1 m⁶A per 5 mRNA molecules.

RNA ligase mediated poly(A) tail assay (PAT assay)

5' phosphorylated DNA oligo adaptor (500 pmol) was linked to the free hydroxyl group at the 3'-end of transcripts (1 µg of total RNA) by T4 RNA ligase 1 (NEB M0204) in the presence of 15% (w/v) PEG 8000 at 25°C for 4 h. Note that the adaptor oligo has a 3'-end dideoxyadenosine to avoid ligation between the adaptors. The ligated RNA (250 ng) was used to generate cDNA with the SuperScript II Reverse Transcriptase (Invitrogen 18064-014) according the manufacturer's protocol using a primer complementary the adaptor. A VSG specific forward primer and an adaptor specific reverse primer were used for the subsequent PCR amplification using Phusion High-Fidelity DNA polymerase (ThermoScientific) with increased MgCl₂ concentration (3.5 mM) and reduced extension temperature (60°C). The amplification products were diluted 1:500 and used as a template in a second amplification (nested PCR) with a second VSG specific forward primer and a second adaptor specific reverse primer. The A0 amplification product (Fig. 6) corresponds to the amplification product without a poly(A) tail. It results from a PCR amplification in which the reverse primer anneals at the end of the 3' UTR immediately upstream of the poly(A) tail. Amplification products were resolved on a 6% TBE-PAGE (polyacrylamide gel electrophoresis) for 1 h at room temperature and stained with gel red for visualization. The length of the poly(A) tail estimated by co-migration of the amplification products with a DNA ladder minus the length of the A0 amplification product.

Statistical analysis of decay curves

Data of the decay of mRNA, length of poly(A) tail and m⁶A signal were fitted in GraphPad Prism to either "Plateau followed by one phase decay" or "one phase decay". The first were used when the variable decay started after an initial constant period. The "one phase decay" method was used when the measured variable decreased since the beginning of the experiment. The curves were adjusted to the data by the method of least squares, from which the decay constant K is estimated. The half-life was calculated by the ln(2)/K. This data is summarized in Supplementary Table 3.

RNase H digestion

2 µg of total RNA was mixed with a complementary DNA oligo (0.2 pmol) in water and incubated 5 min at 70°C, after which temperature was reduced 1°C per min until 37°C. RNA:DNA hybrids were digested by RNase H (Ambion AM2293) for 30 minutes. The reaction was stopped by adding formaldehyde loading buffer and incubating at 70°C for 5 min. For RNase H digestions of VSG2 transcript (Fig. 5), a thermostable RNase H (NEB M0523) was used to reduce unspecific digestion of the abundant VSG117 transcript. Also mRNA, instead of total RNA, was used as the substrate to reduce the background and increase the sensitivity in the detection of VSG117 transcript. The digestion mixture was prepared on ice with 50 ng of mRNA, (0.2 pmol) complementary DNA oligo, and Thermostable RNase H. The reaction mixture was transferred to the pre-warmed thermoblock at 50°C and incubated for 25 minutes.

Immunofluorescence assays

Parasites were pelleted by centrifugation (800 g, 3 min, room temperature), resuspended in the remaining medium and transferred to an microcentrifuge tube. Pellet was resuspended in PBS and immediately fixed 4% v/v formaldehyde with gentle agitation by inversion. Fixed cells were centrifuged, resuspended in PBS and settled on poly-L-lysine coated coverslips for 1 h (for cells to settle by gravity). Parasites were permeabilized in 0,2% Nonidet P-40 in PBS for 5 min and washed in PBS three times for 5 min each. Cells were blocked in 1% BSA, 25 mg/mL glycine, in PBST for 1 h and then incubated with anti-m⁶A antibody (Abcam) 1: 250 (4 µg/ml⁻¹ final concentration with 1% BSA in PBS) for 3 h at room temperature. After washing cells three times with PBS for 15 min each with agitation, cells were incubated with secondary anti-rabbit antibody (Alexa Fluor 488, A11034) for 30 min (protected from light). At the end, cells were washed three times with PBS for 15 min each and DNA stained for 1 min with 1 µg/ml Hoechst. Slides were mounted using Vectashield.

Image acquisition and analysis

Confocal images on fixed *T. brucei* parasites were acquired using a Zeiss confocal Laser Point-Scanning (LSM) 880 Microscope equipped with the Zen 2.1 (black) software with a Plan Apochromat 63x NA 1.40 oil immersion DIC M27 Objective. The laser units used were a Diode 405-430 to excite the 405nm wavelength (corresponding to Hoechst), and an Argon laser to excite the 488nm wavelength (GaAsP detector 525/50 nm) (corresponding to AF488 used as a secondary antibody for m⁶A labelling). Images were acquired in a two-track mode. A pinhole diameter of 1AU for the 488 laser track was used. DIC images in confocal mode were obtained using the 405nm laser line. A digital zoom of 1.2x was used for general quantification, or a digital zoom of 4x for sub-localization analyses. For z-stack acquisition, on average 7-14 slices were obtained to cover all parasite areas per field, with a stack slice of 0.3µm. Images were acquired in multiple fields of view to enable quantification of at least 100 parasites per condition per experiment repeat. Images were analysed using Fiji/ImageJ (imagej.nih.gov/ij/) for background correction, MFI determination and segmentation analysis. 3D rendering and 3D quantifications of m⁶A were performed using Imaris 9.1.0 (BitPlain). Statistical significance was determined using GraphPad Prism (GraphPad Prism Software version 6). Statistical tests used are mentioned in the corresponding Fig. legends. p<0.05 was considered significant.